Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
19
SRNE Quote, Financials, Valuation and Earnings
Last price:
$0.0000
Seasonality move
:
42.73%
Day range:
$0.0018 - $0.0026
52-week range:
$0.0001 - $0.0985
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.01x
P/B ratio:
--
Volume:
583K
Avg. volume:
581.9K
1-year change:
50%
Market cap:
$992.3K
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Sorrento Therapeutics, Inc. has 722122.22% upside to fair value with a price target of -- per share.
SRNE vs. S&P 500
-
Over the past 5 trading days, Sorrento Therapeutics, Inc. has underperformed the S&P 500 by -53.89% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Sorrento Therapeutics, Inc. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sorrento Therapeutics, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Sorrento Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Sorrento Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Sorrento Therapeutics, Inc. reported earnings per share of --.
Enterprise value:
135.1M
EV / Invested capital:
--
Price / LTM sales:
0.01x
EV / EBIT:
--
EV / Revenue:
2.10x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.56x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2022-06-30 | 2023-06-30 | |
| Income Statement | ||||||
| Revenue | $51M | $55M | $64.3M | $11.5M | $15M | |
| Gross Profit | $39.3M | $30.8M | $24.1M | $4.7M | $5.4M | |
| Operating Income | -$288.4M | -$383.7M | -$355.5M | -$91.9M | -$76.8M | |
| EBITDA | -$303.3M | -$366.2M | -$336.1M | -$87.5M | -$71.1M | |
| Diluted EPS | -$1.14 | -$1.53 | -$1.06 | -$0.54 | -$0.17 | |
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $93.5M | $55M | $155.3M | $196M | $133.1M | |
| Total Assets | $587M | $533.1M | $778.9M | $632.1M | $456.7M | |
| Current Liabilities | $112M | $91.3M | $180.5M | $145.3M | $264.9M | |
| Total Liabilities | $532.4M | $452.9M | $593.4M | $496.4M | $654.6M | |
| Total Equity | $54.6M | $80.2M | $185.5M | $135.8M | -$198M | |
| Total Debt | $255.8M | $166.2M | $112.4M | $191.1M | $194.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2022-06-30 | 2023-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$210M | -$319.6M | -$234.6M | -$81M | -$55.7M | |
| Cash From Investing | $40M | -$12.2M | -$11.6M | -$1.7M | -$140K | |
| Cash From Financing | $176.7M | $326.1M | $246.6M | $41.8M | $88.8M | |
| Free Cash Flow | -$221.1M | -$328.3M | -$243.2M | -$83.7M | -$55.8M | |
SRNE
Sector
Market Cap
$992.3K
$27.9M
Price % of 52-Week High
1.83%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.49%
1-Year Price Total Return
50%
-16.66%
Beta (5-Year)
1.119
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0034
200-day SMA
Sell
Level
$0.0032
Bollinger Bands (100)
Sell
Level
0.0048 - 0.0048
Chaikin Money Flow
Sell
Level
-2.1M
20-day SMA
Sell
Level
$0.0042
Relative Strength Index (RSI14)
Sell
Level
35.1088
ADX Line
Sell
Level
11.8855
Williams %R
Neutral
Level
-79.7297
50-day SMA
Sell
Level
$0.0059
MACD (12, 26)
Buy
Level
0.0005
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Sell
Level
-2.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. The Sorrento Therapeutics segment consists of developing a portfolio of next generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. The Scilex segment is largely organized around the company's non-opioid pain management operations. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, SRNE has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SRNE average analyst price target in the past 3 months is --.
-
Where Will Sorrento Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sorrento Therapeutics, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Sorrento Therapeutics, Inc.?
Analysts are divided on their view about Sorrento Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sorrento Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Sorrento Therapeutics, Inc.'s Price Target?
The price target for Sorrento Therapeutics, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SRNE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sorrento Therapeutics, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SRNE?
You can purchase shares of Sorrento Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sorrento Therapeutics, Inc. shares.
-
What Is The Sorrento Therapeutics, Inc. Share Price Today?
Sorrento Therapeutics, Inc. was last trading at $0.0000 per share. This represents the most recent stock quote for Sorrento Therapeutics, Inc.. Yesterday, Sorrento Therapeutics, Inc. closed at $0.0018 per share.
-
How To Buy Sorrento Therapeutics, Inc. Stock Online?
In order to purchase Sorrento Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SRNE Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SRNE
Sector
P/E ratio
--
23.85x
PEG ratio
--
-0.01x
P/B ratio
--
1.81x
Price / LTM sales
0.01x
1.58x
Growth Metrics
SRNE
Sector
Revenue growth
--
4.62%
Earnings growth
--
10.5%
Revenue (5-year growth)
--
6.5%
Earnings forecast
--
-$0.21
Profitability
SRNE
Sector
Profitability FY 2025
--
$3.6M
Return on invested capital
--
-31.87%
Return on assets
--
-28.18%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Nov
22
Next Earnings Date
Dec
21
Estimated Next Earnings Date
Mar
22
Balance Sheet
SRNE
Sector
Total cash
--
$26.4M
Short term investments
--
$25.7M
Total assets
--
$76.9M
Long term debt
--
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
